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Abstract  
Aim: To establish a review in the current literature and to analyze the relation Legionnaires’ 
disease – TNF-α inhibitors, in order to estimate the real indications for such connection. 
Material and Methods: The electronic data for PubMed and Google Scholar have been searched, 
according to the vocabulary: legionellosis, epidemiology, outbreak, diagnosis, pathogenesis, 
therapy, TNF-α inhibitors, indications, side effects, risk of infection. The obtained studies have been 
selected in English, according to the relevance by the topic. 
Results: Selected papers, consisted of ten studies and eight case reports, yielded 35 cases of 
Legionnaires' disease associated with the use of TNF- α inhibitor treatment. 
Discussion: There is a prevailing conclusion for increased risk of serious infections while using 
TNF-α inhibitors and also a deficiency of studies for an association of Legionnaires’ disease with 
the use of TNF-α inhibitors. Sub-diagnosing and no-existence of screening before the anti-TNF-α 
therapy blur the factual profile for the researched relation. The possibility for latent infection has not 
been sufficiently researched. 
Conclusion: There are indications that Legionnaires’ disease in the therapy with TNF-α inhibitors is 
indeed a forthcoming problem. Additional target researches are required in order to establish the 
position of Legionnaires’ disease in the mosaic of anti - TNF-α therapy.  
 
 
 
 
 
 
 
 
 
 
Introduction 
 The introduction of a novel class of drugs 
named “biological agents” more than a decade ago, 
was followed by period of uprising concern regarding 
their safety profile. In spite of the revolutionary role in 
the treatment of broad spectrum of inflammatory 
diseases, it has to be considered that several 
significant side effects might seriously compromise 
the use of these drugs, including the increased 
probability of acquiring an opportunistic infection. 
 Bacteria from the species Legionella were 
included in the microbiological taxonomy in 1977, after 
the first registered outbreak of Legionnaires’ disease 
in the United States of America in 1976 [1]. Genetic, 
phenotypc and antigenic characteristics are described 
elsewhere [2, 3], as well as microbiological diagnostic 
procedures [4]. 91.5%  of   legionellosis cases are 
caused by bacteria belonging to the genus of L. 
pneumophila, and Legionella pneumophila serogroup 
1 is of crucial importance for human infection, being 
responsible for 84.2% of legionellosis cases [5]. 
 Legionellas are primarily found around fresh 
water environments (such as lakes and streams) in 
the nature. Natural reservoirs of fresh water are not 
reservoirs of legionellosis outbreaks. In man-made 
water pipe systems, the largest number of legionella is 
sessile and survives within biofilms. L. pneumophila 
multiplies at temperatures between 25
 o
C and 42
o
C, 
with an optimal growth temperature of 35
o
C [4]. 
Humans are infected by inhalation of legionella-
contaminated aerosols, and the source of these 
aerosols might be different including: taps, showers, 
air-conditioning systems, hospital respiratory therapy 
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devices, spa or natural pools, water fountains, etc. [6]. 
Owing to the unique virulence traits, the bacterium 
survives and is replicated intracellularly, being 
previously phagocytosied by alveolar macrophages 
[3]. 
 Legionella is an opportunistic pathogen since 
in healthy humans the infection is self-limiting and 
these individuals may remain asymptomatic. Risk 
factors associated with legionella infection include: 
older age, male gender, smoking status, chronic 
diseases with or without immunosuppression [6]. 
 Legionellosis usually occurs sporadically, and 
sometimes in outbreaks. It is most frequently 
manifested as pneumonia (the so-called Legionnaires’ 
disease), which is often severe, or as the so-called 
Pontiac fever (flu-like illness) [7]. Newer generation of 
macrolides and azalides (clarithromycin, azithromycin) 
and fluoroquinolones (ciprofloxacin, levofloxacin, 
moxifloxacin) has been shown to penetrate rapidly 
and achieve a high level of concentration in 
phagocytic cells [8], an attribute that makes them 
drugs of choice in Legionnaires’ disease. 
 Legionella spp. is one of the most common 
causative agents of community-acquired pneumonia 
(CAP): 2-15% of all hospitalized patients for CAP in 
Europe and North America are caused by Legionella 
[7], and recent studies suggest an increasing rate of 
legionellosis cases [9]. Legionella spp. has been 
isolated with variable incidence (1-40%) in hospital-
acquired pneumonia (HAP), which has a significantly 
higher mortality rate than CAP (up to 40%) [10]. 
Mortality rate due to Legionella pneumonia is still high 
although since 1990 it has a decreasing tendency, 
from 26% to 10% for CAP [11]. 
 Tumor necrosis factor-α (TNF-α) is a pro-
inflammatory cytokine, which plays a critical role in the 
pathogenesis of different inflammatory and/or 
immunologically-conditioned diseases [12]. TNF-α 
inhibitors are biological agents that specifically target 
this key of inflammation cascade, prevent binding to 
its receptors and thus block its effect. Since the 
introduction of the first TNF-α inhibitor – infliximab – in 
the therapy of rheumatoid arthritis (RA) in 1999 [13] 
until today, two other drugs of the same group have 
also been approved – adalimumab and etanercept, 
and the indications have been expanded on other 
chronic inflammatory/immunologic diseases, both 
rheumatologic and non-rheumatologic ones [14, 15]. 
Infliximab and adalimumab are anti-TNF-α monoclonal 
antibodies, which bind with high affinity to human 
TNF-α and neutralize its biological activity. Etanercept 
is a fusion protein, which acts as a soluble receptor 
and is competitively bound to TNF-α. 
 TNF-α also plays an important role in host 
immune response to infectious pathogens [10, 16], 
being a critical component of both anti-bacterial 
protective and anti-inflammatory response to 
infections, especially with intracellular viable 
microorganisms.  
 The role of TNF-α  and cell-mediated 
immunity in the organism defence from L. 
pneumophila has been well acknowledged and 
documented [17]. TNF-α plays a key role in the 
inhibition of bacterial growth and replication, and 
resolution of Legionella pneumonia [18, 19]. This 
observation has been supported by the relative Th1- 
cytokine profile predominance in patients with 
Legionnaires’ disease [20].  
 Interference with the function of TNF-α with a 
subsequent reduction of tissue levels of bioactive 
TNF-α is beneficial for patients suffering from RA or 
similar diseases, but it raises the question of continual 
supply of effector cells in the infectious loci, thus 
compromising the cell-mediated immunity to 
intracellular microorganisms (including L. 
pneumophila).  In this manner, TNF-α suppression is 
a double-edged sword: by reducing TNF-α high levels 
the inflammation is reduced, but low levels of 
biologically active TNF-α might be associated with an 
increased risk for infections, especially with 
opportunistic microorganisms. 
 In spite of the relatively secure safe profile, 
derived from the phase III of clinical trials [21], lately a 
large number of post-marketing studies report on the 
increased incidence/risk from infection when using 
these agents. Many of them are focused on 
tuberculosis while the remaining “rarer” opportunistic 
pathogens, including legionella, are hardly ever 
subject to observation. 
 The incidence of Legionella pneumonia in 
immunocompromised patients as well as in patients 
receiving anti-TNF-α therapy has not been identified 
[10]. The aim of this study was, based on the available 
literature data, to analyze the relationship between 
Legionnaires’ disease and TNF-α inhibitors, to assess 
whether indices for this relationship are real, and 
depending on the findings gathered - to suggest future 
activities.   
 
Material and Methods 
 To accomplish the aim of this review paper, a 
systematic literature search covering the period 
between 01.01.1977 and 01.02.2013 was performed 
using PubMed and Google Scholar electronic 
databases, to identify all relevant articles (i.e. articles 
reporting the exact cases of Legionella pneumonia 
during TNF- α   inhibitor treatment). The search was 
limited to full text English language papers, using the 
following key words:  legionellosis, epidemiology, 
epidemiological investigation, outbreak, diagnosis, 
pathogenesis, therapy, biological agents, TNF-α, TNF-
α inhibitors, TNF-α blockers, TNF-α antagonists, anti-
TNF-α therapy, indications, side effects, risk of 
infection.  
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Results 
 Selected papers can be divided into case 
reports and studies, both observational and 
interventional. Case reports presented patients who 
experienced Legionnaires’ disease while receiving 
anti-TNF-α therapy for Behcet’s and Chron’s desease, 
psoriasis and RA [10, 22-28]. The results of the 
studies are as follows: 
 The retropective study of Kroesen et al. 
(2003) was conducted in 60 patients with RA treated 
with etanercept or infliximab. Serious bacterial 
infections (including one case of Legionella 
pneumonia) were registered in 11 (18.3%), the 
incidence being 0.181 per TNF-α treatment year vs. 
0.008 per year without treatment in the 2 years 
preceding anti-TNF-α therapy [29].  
 In the prospective observational cohort study 
of 7,664 anti-TNF-α treated and 1,354 DMARD-
treated patients with severe RA from the British 
Society for Rheumatology Biologics Register 
(BSRBR), Dixon et al. (2006) reported that anti-TNF-α 
therapy was not associated with an increased risk of 
overall serious infections compared to non-biological 
DMARDs treatment, nor there was a difference in the 
risk among the three used TNF-α inhibitors. However, 
they reported an increased risk of bacterial 
intracellular infections among patients treated with 
TNF-α inhibitor: of 525 episodes of serious infections 
in TNF- α  inhbitor treated cohort, 19 were bacterial 
intracellular including 2 cases of Legionella 
pneumonia. No bacterial intracellular infection was 
registered in the DMARD-treated cohort [30].  
 The retrospective observational study of 
Curtis et al. (2011) was conducted  in 6992 RA 
patients registered at large US healthcare 
organization and treated with different biological 
agents. It reported hospitalized infection rates in 
patients who were treated for the first time with a TNF-
α inhibitor (infliximab, adalimumab, etanercept) or 
other biological agent (rituximab and abatacept) and 
in “switchers” from one to another biological agent of 
4.6 and 7.0 per 100 patient-years, respectively 
(p<0.0001); the highest rate was registered for 
infliximab in both groups. Among 364 hospitalized 
infections, the majority of 124 (23,7%) were due to 
pneumonia (with no causative organism indicated), 
while 23 (including two cases of Legionella 
pneumonia) were due to “specific site/type of 
infection” [31].  
 By analyzing the RATIO Registry (Recherche 
Axée sur la Tolérance des Biothérapies), designed to 
collect data on opportunistic and severe infections in 
patients treated with ТNF-α inhibitors, Tubach et 
al.reported 10 cases of L. pneumophila pneumonia in 
France during 2004, with an overall legionellosis 
incidence rate in France of 2/100 000 and L. 
pneumophila infection incidence rate of 33-42/100 000 
in patients treated with ТNF-α inhibitors. In one of 
these 10 patients, re-introduction of infliximab was 
followed by second episode of Legionnaires’ disease. 
Only one case of legionellosis in a patient with RA not 
treated with ТNF-α inhibitors was reported during the 
same period [32].  
 Goekoop-Ruiterman et al. (2007) conducted a 
randomized controlled clinical trial in 508 patients, 
designed to compare the clinical and radiographic 
efficacy of four different therapeutic approaches for 
RA, with infliximab included (in different way) in each 
of them. 10 patients (8%) from group 1 experienced 
infection, including one case of  Legionella pneumonia 
[33].  
 By analyzing the Spanish BIOBADASER 
registry (a national drug safety registry of patients with 
rheumatic diseases) Pérez-Sola et al. (2011) reported 
907 episodes of infection in 706 (10%) out of 6,969 
patients. Among 101 (11.1%) episodes of pneumonia, 
25 (24%) were with confirmed etiology, Legonella spp. 
being causative agent in 5 (including 1 fatal) cases. 
The overall infection incidence rate was 53.09/1,000 
patients-years (CI 95%; 49.69-56.66) and pneumonia 
incidence rate was 5.97/1,000 patients-years (CI 95%; 
4.87-7.25) [34].  
 The study of Kohn et al. (2007), conducted to 
evaluate short- and long-term effectiveness and safety 
of infliximab in 83 patients (46 analyzed 
retrospectively and 37 prospectively) with severe 
refractory ulcerative colitis, reported infection as an 
adverse event in 5 patients (6%), including one case 
of fatal Legionella pneumonia [35].  
 The study of Aringer et al. (2009) was 
conducted to examine the adverse events and 
efficacy of infliximab during the long-term follow up of 
13 patients with systemic lups erythematodes (6 
included in an open-label trial, and 7 treated on an 
individual compassionate care basis after standard 
therapy had failed). Short-term and long-term 
treatment revealed infection complications in 5 and 2 
patients (including one case of fatal Legionella 
pneumonia), respectively [36].  
 Panaccione et al. (2011) conducted a phase 
III open-label study to examine the efficacy and safety 
of adalimumab in 304 Canadian patients with 
moderate to severe Crohn’s disease (ACCESS  trial). 
Eight patients (2.6%) experienced serious infections, 
including  Legionella pneumonia in one patient [37].  
 The retrospective  study of Favalli et al. 
(2008) was conducted in terms of examination of 
pattern of utilization and the costs of therapy of 
infliximab, in 95 patients with refractory RA. During the 
observational period of one year, the sole adverse 
event was Legionella pneumonia in one patient 
(1.05%) [38].  
 Cases of Legionella pneumonia associated 
with TNF-α  inhibitor therapy are compiled in Table 1. 
Important thing to notice is partial or complete lack of 
relevant clinical data in 13 out of 35 reported cases, 
mainly in the large studies (exception is the of study of  
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Table  1: Clinical features of the patients with Tumor necrosis factor - ɑ inhibitor – associated Legionnaires’ disease. 
Source 
Age 
/sex 
Indication 
Disease 
duration 
Co -
morbidities 
TNF-ɑ 
inhibitor  
Treatment 
duration 
 
Concomitant 
immunosupre-
ssive therapy 
Infe-
ction 
origin 
Clinical/ 
radiological 
features 
Diagnostic 
modality 
Antibiotic 
therapy 
Outcome  
Beigel et al. 
[10] 
58/M 
CD  
 
12 m. Smoker IFMB N/A 
Azathioprine,  
mesalazine, 
prednisolone 
 
C 
ULP, 
respiratory 
failure 
PCR (+) BAL 
(LP1); LPAg 
(+) (LP1) 
Moxifloxacin 
ICU 
admission. 
Recovered. 
Mancini et 
al. [22] 
30/M 
Behçet’s 
disease  
8 y. 
Pulmonary 
TB 
IFMB 4 w. MTX C 
ULP, 
pleural 
effusion** 
 LPAg (+) 
(LP1) 
 
Levofloxacin 
+ Rifampicin 
Recovered 
Hofmann et 
al. [23] 
26/M CD 2 m. Smoker  IFMB 4 w. 
6-
mercaptopu-
rine, 
prednisone 
N 
BLP, 
ARDS**. 
LPAg (+) 
(LP1) 
 
Azithromycin  
ICU 
admission,  
Recovered 
59/M 
CD  
 
4 m. 
Smoker,  
COPD 
IFMB 
 
4 w. 
Methyl- 
prednisolone 
 
N 
BLP, lung 
abscess, 
ARDS 
LPAg (+) 
(LP1) 
 
Azithromycin 
 
 
ICU 
admission. 
Died. 
Christidis et 
al. [24] 
55/M RA N/A Smoker IFMB 49 w. 
Prednisolone, 
cyclosporine 
A, MTX 
N/A 
BLP,  lung 
cavitation 
LPAg (+) 
(LP1); serology  
(titer 1:512) 
Clarithro-
mycin + 
Rifampicin 
Recovered  
Jinno et al. 
[25] 
67/F RA N/A Smoker  ALMB 2  y. MTX C 
ULP, 
pleural 
effusion 
PCR&DFA (+) 
BAL;  LPAg (+) 
(LP1) 
Moxifloxacin 
+ Rifampicin 
ICU 
admission. 
Recovered 
Wuerz et 
al. [26] 
67/F RA >2 y. 
Hypo- 
thyroidism 
ALMB 10  w. Azathioprine C 
ULP, PE, 
lung 
cavitation** 
Culture (+) 
BAL; LPAg (+) 
(LP1) 
Levofloxacin 
+ Rifampicin, 
Azithromycin 
ICU 
admission, 
Recovered 
Porzio et al. 
[27] 
 
42/M Psoriasis  N/A N/A IFMB 9 m. MTX N/A 
BLP, lung 
cavitation, 
pleural 
effusion** 
PCR (+) BAL, 
LPAg (+) (LP1) 
Levofloxacin 
+ 
Azithromycin 
Recovered  
Epping et 
al. [28] 
26/F CD 2  y. 
Pregnancy 
(6
th
 month)  
IFMB 58 w. None  C ULP** 
L.pneum. (+) 
IgM and IgG; 
LPAg (+) (LP1) 
Erythromycin Recovered  
Kroesen et 
al. [29] 
49/M RA > 7 y. Psoriasis IFX  N/A MTX N/A BLP LPAg (+) (LP1) N/A N/A 
Dixon et al. 
[30] 
59/M RA N/A N/A IFX 32 m. N/A N/A LRTI N/A N/A N/A 
49/M RA N/A N/A IFX 4 m. N/A N/A LRTI N/A N/A N/A 
Curtis et al. 
[31] 
N/A N/A N/A N/A N/A N/A N/A  N/A N/A N/A N/A N/A 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Tubach et 
al. [32] 
43/M RA N/A 
Diabetes 
mellitus 
ALMB  71  w. 
MTX, 
prednisone 
C BLP** LPAg (+) (LP1) FLQ Recovered 
55/F RA 30 y. No  ALMB  26  w. 
MTX , 
prednisone 
C ULP LPAg (+) (LP1) 
Macrolide, 
Rifampicin 
Recovered  
67/M RA 3,5 y. 
Smoker; 
COPD 
 
ETCP 16  w. 
MTX, 
prednisolone  
C 
 
ULP, 
ARDS** 
BAL culture 
(+); LPAg (+) 
(LP1) 
 
Rifampicin, 
FLQ 
ICU 
admission.  
Recovered 
46/F 
Pyoderma 
gangreno-
sum 
1,5 y. 
Primary  
thrombo- 
cythemia 
IFMB 73  w. 
Prednisone, 
pipobroman 
C 
BLP, 
pleural 
effusion, 
ARDS**  
LPAg (+) (LP1) 
Macrolide, 
Rifampicin 
ICU 
admission.  
58/M Psoriasis 45 y. Smoker IFMB  3 w. None  C  
ULP, 
pleural 
Effusion 
LPAg (+); PCR 
(+) 
sputum (LP1) 
Macrolide, 
FQL 
Recovered 
40/M RA  4 y. 
Diabetes 
mellitus, 
smoker; 
COPD 
ALMB  34 w. 
Sulfasalazine, 
betametha-
sone 
 
C 
 
ULP** LPAg (+) (LP1)  
Rifampicin, 
FLQ 
Recovered 
45/F RA 33 y. Smoker ALMB  36 w. 
MTX, 
prednisone 
C ULP** LPAg (+) (LP1)  
Macrolide, 
FLQ 
Recovered 
66/F 
RA   
 
10 y. None ALMB  45 w. MTX 
C 
 
BLP, 
ARDS** 
LPAg (-); 
seroconversion 
1:16  1:256 
(LP6) 
FLQ, 
ceftriaxone  
Recovered 
 
 
  
47/M RA 3 y. 
Smoker, 
water 
cleaning 
system  
worker 
ALMB  50 w. Prednisone  C 
BLP, 
ARDS, 
pneumo-
thorax 
LPAg (+); BAL 
culture (+) 
(LP1) 
Rifampicin, 
FLQ  
 
ICU 
admission, 
Recovered 
69/F 
RA 
 
10 y. None ETCP^  45 w. 
MTX, 
prednisone 
C 
 
BLP** LPAg (+) (LP1)  FLQ  Recovered 
27/F 
CD   
 
5 y. None IFMB  1 w. 
Azathioprine , 
prednisone 
 
C  ULP, ARDS 
LPAg (+); BAL 
culture 
(+)(LP1) 
Rifampicin, 
FLQ 
ICU 
admission. 
Recovered 
Goekoop 
Ruiterman  
et al. [33] 
N/A RA N/A N/A N/A N/A N/A N/A Pneumonia N/A N/A N/A 
Peŕez-Sola 
et al. [34]* 
N/A N/A N/A N/A N/A 
Median = 
28 (6-45) 
m. 
N/A N/A Pneumonia  N/A N/A 
Died/ 
N/A  
Kohn et al. 
[35] 
71/M UC 2 y. N/A IFMB 11 d. 
Gluco-
corticoids, 
mesalazine 
N/A 
Pneumonia, 
lung 
abscess** 
PCR (+) 
sputum  (LP1) 
N/A Died 
Aringer et 
al. [36] 
N/A SLE N/A N/A IFMB 12 m. N/A C Pneumonia N/A N/A 
ICU 
admission. 
Died. 
Panaccione 
et al. [37] 
N/A CD N/A N/A ALMB N/A N/A N/A Pneumonia N/A N/A N/A 
Favalli et 
al. [38] 
N/A RA N/A N/A IFMB N/A N/A N/A Pneumonia N/A N/A N/A 
 
Abbreviations: ALMB=adalimumab; ARDS=acute respiratory distress syndrome; BLP=bilateral pneumonia; BAL=bronchoalveolar lavage; CD=Chron’s disease; COPD= chronic obstructive pulmonary 
disease; C=community acquired pneumonia; d=day; ETCP=etanercept; F= female; FLQ=fluoroquinolone; IFMB=infliximab; ICU=intensive care unit; LRTI=low respiratory tract infection; LP1=Legionella 
pneumophylla serogroup1; LP6=Legionella pneumophylla serogroup 6; LPAg=Legionella pneumophylla urinary antigen; МТХ=metotrexate; M= male; m=month; N= nosocomial pneumonia; N/A= 
information not available; PE=pulmonary embolism;PCR=polymerase chain reaction; RA=rheumatoid arthritis; SLE=systemic lupus erythematodes UC=ulcerative colitis;ULP=unilateral pneumonia; 
y=year; *Five patients share identical clinical findings, with exception of the outcome  (one died; for other not available).; **Presence of clinical features beside respiratory system; ^ This patient 
experienced previous treatment with infliximab.  
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Tubach et al.[32]). The remaining reported cases are 
characterized with: (1) predominance of infliximab and 
adalimumab treated patients (25/27 patients); (2) high 
ICU admission rate (10/23 patients, i.e. 43.47%) and 
high mortality rate (4/23 patients, i.e.17.39%); (3) 
frequent concomitant therapy with other 
immunosuppressive drugs (20/22 patients), and co-
morbidities (16/20 patients); (4) accompanying pleural 
effusion (5/22 patients) and pulmonary cavitations 
(5/22 patients). The case of Legionella pneumonia in 
a pregnant woman receiving TNF-α inhibitor [28] is 
particularly intriguing, having in mind that a patient 
with three concomitant immunomodulatory conditions 
(pregnancy, Crohn’s disease and TNF-α inhibitor 
therapy) experienced quite a mild form of the disease, 
with full recovery under erythromycin therapy and 
giving birth to a healthy child.  
 
Discussion 
 While reviewing the literature, one can notice 
that majority of studies suggest existence of an 
increased risk of serious infections (i.e. infection that 
led to hospitalization, death or required intravenous 
antibiotic treatment [30]) in patients treated with TNF-
α inhibitors, especially of those caused by intracellular 
microorganisms, without focusing on Legionnaires’ 
disease as a separate entity. Therefore, L. 
pneumophila infections are rarely described in 
patients receiving such therapy [32]. The study of 
Tubach et al. specifically analyzes development of 
Legionnaires’ disease in patients receiving TNF-α 
therapy. A striking fact revealed from RATIO registry 
[32] is the large discrepancy between the overall  
legionellosis incidence rate in France in 2004 (2/100 
000) and L. pneumophila infection incidence rate in 
patients treated with ТNF-α inhibitors in the same year 
(33-42/100 000). The relative risk of 16.5-21 in this 
treated population compared to the relative risk in 
general population of France indirectly confirms the 
role of ТNF-α in L. pneumophila infection. It is obvious 
that the probability for Legionnaires’ disease 
development in patients receiving treatment with ТNF-
α inhibitors is greater than the overall risk in the 
general population in France. However, the influence 
of the disordered immunologic milieu on risk 
increasing is not to be neglected. In order to obtain 
conclusive data, the L. pneumophila infection rate has 
to be compared in patients receiving vs. patients not 
receiving ТNF-α inhibitor (i.e. receiving non-biological 
DMARDs or placebo), who suffer from the same 
disease with same severity, and have no co-
morbidities and no concurrent immunosupressive 
treatment. Unfortunately, there is a lack of such data. 
 An intriguing issue in this study is the 
appearance of second episode of confirmed 
Legionnaires’ disease (without differentiation weather 
it was a relapse or a new exogenous infection) in one 
of the ten patients with Legionnaires’ disease, 
following the re-introducing of treatment with infliximab 
[32]. Having in mind the reoccurrence of antigenuria 
with a concomitant negative culture and PCR finding 
from lower airways secretions in this patient, it is 
inevitable to think of the hypothetic possibility of a 
“dormant” state of the bacteria after the first contact 
with the host, with reactivation of endogenous 
infection after repeated use of  ТNF-α inhibitor, that 
actually re-established the state of 
immunosuppression. To date, the possibilities of 
development of a latent infection with intracellular 
legionella has not been thoroughly investigated nor 
were presented such a data in the literature. 
Additional research is necessary since existence of 
such a state of the bacterium might have implications 
on the therapy and prophylaxis of the disease.  
 It is a well-known fact that there is an 
increased risk for tuberculosis development in patients 
receiving anti-ТNF-α therapy, as well as an existence 
of latent infection with this intracellular bacterium [16, 
39]. Numerous reports on the association of 
tuberculosis and the usage of these therapeutic 
agents have resulted in international 
recommendations that impose screening for 
tuberculosis before initiation of ТNF-α inhibitor therapy 
[14]. There is no such established screening protocol 
for the other intracellular pathogens, including L. 
pneumophila [10, 32]. Achieving consensus on the 
topic of screening will no doubt need a longer period, 
since conditioned by fulfilment of the following 
prerequisites to overcome under-diagnosis of 
Legionnaires’ disease:     
 1. Enhancing availability of diagnostic tools. 
The two crucial diagnostic procedures (i.e. culture 
confirmation and PCR) are expensive, requiring 
sophisticated equipment and professional skills, and 
so affordable in few laboratories worldwide [4].  
 2. Providing detailed guidance for 
management of Legionella pneumonia. Current 
guidelines of European Respiratory Society [40] and 
American Thoracic Society/Infectious Disease Society 
of America [41] recommend testing on Legionella 
primarily in immunocompetent hospitalized patient in 
whom clinical or epidemiological suspicion for this 
infection emerges, considering the outpatient testing 
as “optional”. In practice, Legionella pneumonia is 
radiographically and clinically indistinguishable from 
other forms of pneumonia [42], does not always have 
a severe clinical presentation requiring hospital 
treatment [43] and outpatient testing is rarely 
performed. Since there is a lack of precise guidelines, 
suspicion of Legionnaires’ disease in patients 
receiving treatment with TNF-α inhibitor relies on 
subjective assessment of the physician who monitors 
the therapeutic response.  
 3.  Improvement of passive and awkward 
disease-reporting networks [9]. Collected 
epidemiological data on Legionnaires’ disease do not 
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refer to the real situation and underestimate the size 
of the problem. In favour of this statement speaks the 
discrepancy between the registered incidence and the 
estimated number of cases with Legionnaires’ disease 
[9, 10, 43]. 
 The need to overcome the problem of under-
diagnosed Legionnaires’ disease should not 
marginalize contemplation over introduction of 
screening test for L. pneumophila in patients – 
candidates for therapy with TNF-α inhibitor. A feasible 
solution, in lack of exact testing opportunity, might be 
detection of soluble legionella antigens in urine 
samples. The method is simple, rapid, cheap, and 
widely available, with high specificity and satisfactory 
sensitivity. Its diagnostic value is limited to L. 
pneumophila serogroup 1, but the promising fact for 
this screening test is that >80% of the infections are 
caused exactly by this strain. In addition to the safety 
of the patients, the results might have broader 
meaning since the screening test would comprise a 
quite large population [13]. The interpretation of the 
results of such a large group would presumably have 
implications on broadening the knowledge and 
fulfilling the gaps about the pathogenesis of the 
infection. 
 The first giant step in perceiving the true 
position of TNF-α inhibitors in increasing the 
susceptibility to legionella infection was taken by 
Directive concerning this issue, released on 7
th
 of 
September 2011 by Food and Drug Administration in 
the USA. It said that the black box warning information 
for all of the TNF-α inhibitors had to be updated to 
include the increased risk for serious and sometimes 
fatal infection with Listeria and Legionella. This 
Directive was a result of 80 cases (of which 14 with 
fatal outcome) registered in the period between 1999 
and 2012, who developed Legionella pneumonia after 
having received TNF-α inhibitors [44]. At the moment, 
relevant European institutions (European Working 
Group on Legionella Infection (EWGLI), European 
Centre for Disease Prevention and Control (ECDC)) 
do not have such an alert and their recommendations 
are a general advice for diagnosis and registration of 
legionellosis [6, 45], as well as surveillance in the 
countries included in the network of these institutions. 
 We are aware while TNF-α role in controlling 
infection against L. pneumophilla (as described 
above) provides pathophysiologic base supporting 
predisposition for legionellosis in patients treated with 
TNF-ɑ inhibitor, it is not sufficient per se to establish 
direct causative relationship between these two 
entities. Nevertheless, the present review serves to 
highlight the possibility that TNF-ɑ inhibitors, beside 
other reported opportunistic infections [22], might 
predispose the infection with L.pneumophylla too. 
Epidemiological support for this hypothesis arises 
from the largest case-series in the literature – the 
French registry of patients receiving TNF-ɑ inhibitors 
[32], the FDA Directive [44], as well as from the fact 
that legionellosis was rarely reported in rheumatic 
patients not receiving TNF-ɑ inhibitor [32]. 
 Given the fact that this is a severe and 
potentially fatal but curable disease, maintaining a 
high index of clinical vigilance and systematic 
assessment of every symptom by the treating 
physician, is important to diagnose in time and 
adequately treat these patients (i.e. empiric 
administration of an antibiotic comprising legionella, 
until the aetiology of pneumonia is confirmed). A long-
term follow-up might help to define better the clinical 
risk carried by anti-TNF-α agents in everyday clinical 
practice.  
 Previous review has several limitations. The 
exemption of non-English papers and relevant 
abstracts certainly has an impact on completing the 
picture of the topic discussed (e.g. additional cases 
from RATIO registry published in EULAR 2010 
abstract book by Tubach et al. are not included in this 
review). The second issue relates to the imbalanced 
immune system in the population that is subject of this 
review, due to the primary chronic inflammatory 
disease. In addition, it is modulated by the 
conventional immunosuppressive therapy (cytostatics, 
glucocorticoids, non-biological DMARDs) and other 
co-morbid conditions, which altogether complicates 
the appropriate interpretation of the results from 
studies and clinical trials. Finally, previous studies 
have been performed mainly in patients with RA. 
However, this is not surprising having in mind that 
they comprise the majority of patients eligible to enter 
this type of studies: RA is the main indication for use 
of TNF-α inhibitor therapy [32] and an estimated 20% 
of RA patients receive such treatment [13]. 
 In conclusion, to specify the characteristics of 
this relationship, it is necessary to define the actual 
size of the problem by diagnosing and reporting of 
legionellosis on regular basis. Also, additional target 
investigations and trials are needed to find the exact 
place of Legionnaires’ disease in the mosaic of anti-
TNF-α therapy. The future research on Legionnaires’ 
disease in patients who are candidates for anti-TNF-α 
inhibitors therapy, should focus on several important 
issues: 1) Chemoprophylaxis [8]; 2) Investigations of 
intracellular cycle of L. pneumophila (potential 
development of screening test for detection of latent 
infection, analogue to Interferon-γ Release Assays in 
latent tuberculosis infection (LTBI) [39]); 3) 
Development of new TNF-α inhibitors. Differences 
have been reported in the risk of reactivation of LTBI 
when infliximab and etanercept have been used [16, 
46] as well as differences in pharmacokinetics and 
modulation of TNF-α activity between the existing 
TNF-α inhibitors [47] The future of drugs directed 
against TNF-α lays in the creation of therapeutic 
agents adjusted to both endogenous kinetics of TNF-α 
and differences of TNF-α-biology in different diseases; 
4) Vaccine. In vivo experiments on guinea-pigs 
showed that bacterial parts [48], secretory products 
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[49] and live avirulent vaccine [50] stimulated creation 
of cell-mediated protective immunity. Results from 
these animal models have not been verified and 
confirmed through clinical trials, and vaccine against 
Legionnaires’ disease has not been developed yet [8]; 
5) Engagement of public health system: continuing 
education and training of healthcare professionals 
who prescribe TNF-α inhibitors [13]; additional 
prevention strategies [29] and population-based 
studies to define the exclusion criteria in candidates 
for biological therapy [13]; precise registration of 
adverse effects; education of patients for early self-
recognition of infection symptoms and signs and 
option for self-reporting the side effects of therapy; 
and 6) Infection control. Patients receiving TNF-α 
inhibitor therapy have to be advised to avoid exposure 
to aerosols from different water supply systems. Since 
the disease is not transmitted from human to human, 
the primary place in the infection control is given to 
surveillance of water supply systems (particularly in 
health care facilities), followed by use of efficacious 
disinfection agents [4, 6]. 
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